#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	Alterations	_
1-2	12-14	in	_
1-3	15-24	intrinsic	_
1-4	25-48	fronto-thalamo-parietal	_
1-5	49-61	connectivity	_
1-6	62-65	are	_
1-7	66-76	associated	_
1-8	77-81	with	_
1-9	82-91	cognitive	_
1-10	92-99	control	_
1-11	100-108	deficits	_
1-12	109-111	in	_
1-13	112-121	psychotic	_
1-14	122-131	disorders	_
1-15	132-139	Despite	_
1-16	140-141	a	_
1-17	142-149	growing	_
1-18	150-156	number	_
1-19	157-159	of	_
1-20	160-167	reports	_
1-21	168-173	about	_
1-22	174-185	alterations	_
1-23	186-188	in	_
1-24	189-206	intrinsic/resting	_
1-25	207-212	brain	_
1-26	213-221	activity	_
1-27	222-230	observed	_
1-28	231-233	in	_
1-29	234-242	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-30	243-247	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-31	248-257	psychotic	_
1-32	258-267	disorders	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
1-33	268-269	,	_
1-34	270-275	their	_
1-35	276-285	relevance	_
1-36	286-288	to	_
1-37	289-305	well-established	_
1-38	306-315	cognitive	_
1-39	316-323	control	_
1-40	324-332	deficits	_
1-41	333-335	in	_
1-42	336-340	this	_
1-43	341-348	patient	_
1-44	349-354	group	_
1-45	355-357	is	_
1-46	358-361	not	_
1-47	362-366	well	_
1-48	367-377	understood	_
1-49	378-379	.	_

2-1	380-382	88	_
2-2	383-393	clinically	_
2-3	394-404	stabilized	http://maven.renci.org/NeuroBridge/neurobridge#RandomizedControlTrial
2-4	405-413	patients	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
2-5	414-418	with	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
2-6	419-420	a	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
2-7	421-430	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
2-8	431-439	disorder	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
2-9	440-443	and	_
2-10	444-446	50	_
2-11	447-454	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-12	455-463	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-13	464-476	participated	_
2-14	477-479	in	_
2-15	480-481	a	_
2-16	482-495	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-17	496-504	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-18	505-514	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-19	515-522	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-20	523-528	study	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-21	529-530	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-22	531-537	rs-MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-23	538-539	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-24	540-543	and	_
2-25	544-553	performed	_
2-26	554-556	an	_
2-27	557-568	antisaccade	_
2-28	569-573	task	_
2-29	574-576	in	_
2-30	577-580	the	_
2-31	581-591	laboratory	_
2-32	592-594	to	_
2-33	595-601	assess	_
2-34	602-611	voluntary	_
2-35	612-622	inhibitory	_
2-36	623-630	control	_
2-37	631-638	ability	_
2-38	639-640	.	_

3-1	641-649	Deficits	_
3-2	650-652	on	_
3-3	653-657	this	_
3-4	658-662	task	_
3-5	663-666	are	_
3-6	667-668	a	_
3-7	669-685	well-established	_
3-8	686-695	biomarker	_
3-9	696-702	across	_
3-10	703-712	psychotic	_
3-11	713-722	disorders	_
3-12	723-725	as	_
3-13	726-728	we	_
3-14	729-734	found	_
3-15	735-737	in	_
3-16	738-741	the	_
3-17	742-749	present	_
3-18	750-757	patient	_
3-19	758-764	sample	_
3-20	765-766	.	_

4-1	767-772	First	_
4-2	773-774	,	_
4-3	775-783	regional	_
4-4	784-792	cerebral	_
4-5	793-801	function	_
4-6	802-805	was	_
4-7	806-815	evaluated	_
4-8	816-818	by	_
4-9	819-828	measuring	_
4-10	829-832	the	_
4-11	833-842	amplitude	_
4-12	843-845	of	_
4-13	846-849	low	_
4-14	850-859	frequency	_
4-15	860-872	fluctuations	_
4-16	873-874	(	_
4-17	875-879	ALFF	_
4-18	880-881	)	_
4-19	882-884	in	_
4-20	885-891	rs-MRI	_
4-21	892-896	BOLD	_
4-22	897-904	signals	_
4-23	905-906	.	_

5-1	907-909	We	_
5-2	910-915	found	_
5-3	916-923	reduced	_
5-4	924-928	ALFF	_
5-5	929-931	in	_
5-6	932-940	patients	_
5-7	941-943	in	_
5-8	944-951	regions	_
5-9	952-957	known	_
5-10	958-960	to	_
5-11	961-963	be	_
5-12	964-972	relevant	_
5-13	973-975	to	_
5-14	976-987	antisaccade	_
5-15	988-992	task	_
5-16	993-1004	performance	_
5-17	1005-1014	including	_
5-18	1015-1024	bilateral	_
5-19	1025-1032	frontal	_
5-20	1033-1036	eye	_
5-21	1037-1043	fields	_
5-22	1044-1045	(	_
5-23	1046-1049	FEF	_
5-24	1050-1051	)	_
5-25	1052-1053	,	_
5-26	1054-1067	supplementary	_
5-27	1068-1071	eye	_
5-28	1072-1078	fields	_
5-29	1079-1080	(	_
5-30	1081-1084	SEF	_
5-31	1085-1086	)	_
5-32	1087-1090	and	_
5-33	1091-1099	thalamus	_
5-34	1100-1101	.	_

6-1	1102-1108	Second	_
6-2	1109-1110	,	_
6-3	1111-1116	areas	_
6-4	1117-1121	with	_
6-5	1122-1126	ALFF	_
6-6	1127-1138	alterations	_
6-7	1139-1143	were	_
6-8	1144-1148	used	_
6-9	1149-1151	as	_
6-10	1152-1156	seed	_
6-11	1157-1162	areas	_
6-12	1163-1165	in	_
6-13	1166-1177	whole-brain	_
6-14	1178-1188	functional	_
6-15	1189-1201	connectivity	_
6-16	1202-1203	(	_
6-17	1204-1206	FC	_
6-18	1207-1208	)	_
6-19	1209-1217	analysis	_
6-20	1218-1219	.	_

7-1	1220-1227	Altered	_
7-2	1228-1230	FC	_
7-3	1231-1234	was	_
7-4	1235-1243	observed	_
7-5	1244-1246	in	_
7-6	1247-1248	a	_
7-7	1249-1272	fronto-thalamo-parietal	_
7-8	1273-1280	network	_
7-9	1281-1285	that	_
7-10	1286-1289	was	_
7-11	1290-1300	associated	_
7-12	1301-1305	with	_
7-13	1306-1316	inhibition	_
7-14	1317-1322	error	_
7-15	1323-1327	rate	_
7-16	1328-1330	in	_
7-17	1331-1339	patients	_
7-18	1340-1343	but	_
7-19	1344-1347	not	_
7-20	1348-1350	in	_
7-21	1351-1359	controls	_
7-22	1360-1361	.	_

8-1	1362-1364	In	_
8-2	1365-1373	contrast	_
8-3	1374-1375	,	_
8-4	1376-1382	faster	_
8-5	1383-1387	time	_
8-6	1388-1390	to	_
8-7	1391-1399	generate	_
8-8	1400-1401	a	_
8-9	1402-1409	correct	_
8-10	1410-1421	antisaccade	_
8-11	1422-1425	was	_
8-12	1426-1436	associated	_
8-13	1437-1441	with	_
8-14	1442-1444	FC	_
8-15	1445-1447	in	_
8-16	1448-1451	FEF	_
8-17	1452-1455	and	_
8-18	1456-1459	SEF	_
8-19	1460-1462	in	_
8-20	1463-1471	controls	_
8-21	1472-1475	but	_
8-22	1476-1480	this	_
8-23	1481-1487	effect	_
8-24	1488-1491	was	_
8-25	1492-1495	not	_
8-26	1496-1500	seen	_
8-27	1501-1503	in	_
8-28	1504-1512	patients	_
8-29	1513-1514	.	_

9-1	1515-1520	These	_
9-2	1521-1529	findings	_
9-3	1530-1539	establish	_
9-4	1540-1541	a	_
9-5	1542-1553	behavioural	_
9-6	1554-1563	relevance	_
9-7	1564-1566	of	_
9-8	1567-1580	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
9-9	1581-1585	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
9-10	1586-1594	findings	_
9-11	1595-1597	in	_
9-12	1598-1607	psychotic	_
9-13	1608-1617	disorders	_
9-14	1618-1619	,	_
9-15	1620-1623	and	_
9-16	1624-1630	extend	_
9-17	1631-1639	previous	_
9-18	1640-1647	reports	_
9-19	1648-1650	of	_
9-20	1651-1662	alterations	_
9-21	1663-1665	in	_
9-22	1666-1689	fronto-thalamo-parietal	_
9-23	1690-1697	network	_
9-24	1698-1708	activation	_
9-25	1709-1715	during	_
9-26	1716-1727	antisaccade	_
9-27	1728-1739	performance	_
9-28	1740-1744	seen	_
9-29	1745-1747	in	_
9-30	1748-1758	task-based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
9-31	1759-1763	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
9-32	1764-1771	studies	_
9-33	1772-1773	.	_

10-1	1774-1782	Material	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1783-1786	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1787-1794	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1795-1803	Subjects	_
10-5	1804-1815	Antisaccade	_
10-6	1816-1827	performance	_
10-7	1828-1831	was	_
10-8	1832-1840	assessed	_
10-9	1841-1843	in	_
10-10	1844-1846	88	_
10-11	1847-1855	patients	_
10-12	1856-1860	with	_
10-13	1861-1862	a	_
10-14	1863-1872	psychotic	_
10-15	1873-1881	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
10-16	1882-1883	(	_
10-17	1884-1897	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-18	1898-1902	N=32	_
10-19	1903-1904	,	_
10-20	1905-1920	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
10-21	1921-1929	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
10-22	1930-1934	N=13	_
10-23	1935-1936	,	_
10-24	1937-1940	and	_
10-25	1941-1948	bipolar	_
10-26	1949-1957	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
10-27	1958-1962	with	_
10-28	1963-1972	psychotic	_
10-29	1973-1981	features	_
10-30	1982-1986	N=43	_
10-31	1987-1988	)	_
10-32	1989-1992	and	_
10-33	1993-1995	50	_
10-34	1996-2003	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-35	2004-2011	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-36	2012-2024	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-37	2025-2032	studied	_
10-38	2033-2035	at	_
10-39	2036-2039	the	_
10-40	2040-2047	Chicago	_
10-41	2048-2052	site	_
10-42	2053-2055	of	_
10-43	2056-2059	the	_
10-44	2060-2066	B-SNIP	_
10-45	2067-2077	consortium	_
10-46	2078-2080	as	_
10-47	2081-2090	described	_
10-48	2091-2101	previously	_
10-49	2102-2103	.	_

11-1	2104-2113	Diagnoses	_
11-2	2114-2118	were	_
11-3	2119-2123	made	_
11-4	2124-2126	by	_
11-5	2127-2128	a	_
11-6	2129-2138	consensus	_
11-7	2139-2146	process	_
11-8	2147-2152	using	_
11-9	2153-2156	all	_
11-10	2157-2166	available	_
11-11	2167-2175	clinical	_
11-12	2176-2187	information	_
11-13	2188-2197	including	_
11-14	2198-2201	the	_
11-15	2202-2212	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
11-16	2213-2221	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
11-17	2222-2231	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
11-18	2232-2235	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
11-19	2236-2239	DSM	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
11-20	2240-2242	IV	_
11-21	2243-2244	.	_

12-1	2245-2253	Patients	_
12-2	2254-2258	were	_
12-3	2259-2269	clinically	_
12-4	2270-2276	stable	_
12-5	2277-2280	and	_
12-6	2281-2290	receiving	_
12-7	2291-2301	consistent	_
12-8	2302-2323	psychopharmacological	_
12-9	2324-2333	treatment	_
12-10	2334-2337	for	_
12-11	2338-2340	at	_
12-12	2341-2346	least	_
12-13	2347-2350	one	_
12-14	2351-2356	month	_
12-15	2357-2358	.	_

13-1	2359-2366	Current	_
13-2	2367-2375	symptoms	_
13-3	2376-2379	and	_
13-4	2380-2389	cognitive	_
13-5	2390-2396	status	_
13-6	2397-2401	were	_
13-7	2402-2410	assessed	_
13-8	2411-2416	using	_
13-9	2417-2425	standard	_
13-10	2426-2432	rating	_
13-11	2433-2439	scales	_
13-12	2440-2441	,	_
13-13	2442-2447	Table	_
13-14	2448-2449	I	_
13-15	2450-2451	(	_
13-16	2452-2457	Table	_
13-17	2458-2459	I	_
13-18	2460-2461	S	_
13-19	2462-2463	)	_
13-20	2464-2465	.	_

14-1	2466-2475	Inclusion	_
14-2	2476-2484	criteria	_
14-3	2485-2488	for	_
14-4	2489-2492	all	_
14-5	2493-2501	subjects	_
14-6	2502-2506	were	_
14-7	2507-2508	:	_
14-8	2509-2510	(	_
14-9	2511-2512	1	_
14-10	2513-2514	)	_
14-11	2515-2518	age	_
14-12	2519-2524	15–65	_
14-13	2525-2526	;	_
14-14	2527-2528	(	_
14-15	2529-2530	2	_
14-16	2531-2532	)	_
14-17	2533-2537	WRAT	_
14-18	2538-2545	reading	_
14-19	2546-2551	score	_
14-20	2552-2553	≥	_
14-21	2554-2556	65	_
14-22	2557-2558	;	_
14-23	2559-2560	(	_
14-24	2561-2562	3	_
14-25	2563-2564	)	_
14-26	2565-2567	no	_
14-27	2568-2575	history	_
14-28	2576-2578	of	_
14-29	2579-2589	neurologic	_
14-30	2590-2597	illness	_
14-31	2598-2600	or	_
14-32	2601-2609	systemic	_
14-33	2610-2617	disease	_
14-34	2618-2619	;	_
14-35	2620-2621	(	_
14-36	2622-2623	4	_
14-37	2624-2625	)	_
14-38	2626-2633	minimum	_
14-39	2634-2636	of	_
14-40	2637-2642	20/40	_
14-41	2643-2649	acuity	_
14-42	2650-2651	(	_
14-43	2652-2656	with	_
14-44	2657-2659	or	_
14-45	2660-2667	without	_
14-46	2668-2678	correction	_
14-47	2679-2680	)	_
14-48	2681-2682	,	_
14-49	2683-2684	(	_
14-50	2685-2686	5	_
14-51	2687-2688	)	_
14-52	2689-2691	no	_
14-53	2692-2699	history	_
14-54	2700-2702	of	_
14-55	2703-2712	substance	_
14-56	2713-2718	abuse	_
14-57	2719-2725	within	_
14-58	2726-2729	the	_
14-59	2730-2734	last	_
14-60	2735-2740	month	_
14-61	2741-2743	or	_
14-62	2744-2753	substance	_
14-63	2754-2764	dependence	_
14-64	2765-2771	within	_
14-65	2772-2775	the	_
14-66	2776-2780	last	_
14-67	2781-2786	three	_
14-68	2787-2793	months	_
14-69	2794-2795	,	_
14-70	2796-2799	and	_
14-71	2800-2808	negative	_
14-72	2809-2814	urine	_
14-73	2815-2825	toxicology	_
14-74	2826-2828	on	_
14-75	2829-2839	assessment	_
14-76	2840-2843	day	_
14-77	2844-2845	,	_
14-78	2846-2847	(	_
14-79	2848-2849	6	_
14-80	2850-2851	)	_
14-81	2852-2854	no	_
14-82	2855-2866	potentially	_
14-83	2867-2875	sedating	_
14-84	2876-2886	medication	_
14-85	2887-2888	,	_
14-86	2889-2892	i.e	_
14-87	2893-2894	.	_

15-1	2895-2910	benzodiazepines	_
15-2	2911-2912	,	_
15-3	2913-2916	and	_
15-4	2917-2918	(	_
15-5	2919-2920	7	_
15-6	2921-2922	)	_
15-7	2923-2927	head	_
15-8	2928-2939	translation	_
15-9	2940-2941	<	_
15-10	2942-2947	1.5mm	_
15-11	2948-2951	and	_
15-12	2952-2960	rotation	_
15-13	2961-2962	<	_
15-14	2963-2967	1.5°	_
15-15	2968-2974	during	_
15-16	2975-2979	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
15-17	2980-2988	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
15-18	2989-2990	.	_

16-1	2991-3000	Inclusion	_
16-2	3001-3009	criteria	_
16-3	3010-3013	for	_
16-4	3014-3021	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
16-5	3022-3030	subjects	_
16-6	3031-3043	additionally	_
16-7	3044-3052	included	_
16-8	3053-3054	:	_
16-9	3055-3056	(	_
16-10	3057-3058	1	_
16-11	3059-3060	)	_
16-12	3061-3063	no	_
16-13	3064-3072	personal	_
16-14	3073-3075	or	_
16-15	3076-3082	family	_
16-16	3083-3090	history	_
16-17	3091-3092	(	_
16-18	3093-3105	first-degree	_
16-19	3106-3114	relative	_
16-20	3115-3116	)	_
16-21	3117-3119	of	_
16-22	3120-3129	psychotic	_
16-23	3130-3132	or	_
16-24	3133-3140	bipolar	_
16-25	3141-3149	disorder	_
16-26	3150-3151	;	_
16-27	3152-3153	(	_
16-28	3154-3155	2	_
16-29	3156-3157	)	_
16-30	3158-3160	no	_
16-31	3161-3168	history	_
16-32	3169-3171	of	_
16-33	3172-3181	recurrent	_
16-34	3182-3192	depression	_
16-35	3193-3194	;	_
16-36	3195-3198	and	_
16-37	3199-3200	(	_
16-38	3201-3202	3	_
16-39	3203-3204	)	_
16-40	3205-3207	no	_
16-41	3208-3215	history	_
16-42	3216-3218	of	_
16-43	3219-3228	psychosis	_
16-44	3229-3237	spectrum	_
16-45	3238-3249	personality	_
16-46	3250-3256	traits	_
16-47	3257-3264	defined	_
16-48	3265-3267	as	_
16-49	3268-3275	meeting	_
16-50	3276-3280	full	_
16-51	3281-3283	or	_
16-52	3284-3290	within	_
16-53	3291-3294	one	_
16-54	3295-3303	criteria	_
16-55	3304-3306	of	_
16-56	3307-3308	a	_
16-57	3309-3316	Cluster	_
16-58	3317-3318	A	_
16-59	3319-3320	(	_
16-60	3321-3330	psychosis	_
16-61	3331-3339	spectrum	_
16-62	3340-3341	)	_
16-63	3342-3349	Axis-II	_
16-64	3350-3359	diagnosis	_
16-65	3360-3361	.	_

17-1	3362-3365	The	_
17-2	3366-3372	median	_
17-3	3373-3377	time	_
17-4	3378-3381	for	_
17-5	3382-3392	completion	_
17-6	3393-3395	of	_
17-7	3396-3399	the	_
17-8	3400-3404	full	_
17-9	3405-3413	protocol	_
17-10	3414-3417	was	_
17-11	3418-3421	two	_
17-12	3422-3426	days	_
17-13	3427-3428	.	_

18-1	3429-3431	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
18-2	3432-3435	and	_
18-3	3436-3438	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
18-4	3439-3447	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
18-5	3448-3456	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
18-6	3457-3466	resonance	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
18-7	3467-3473	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
18-8	3474-3478	were	_
18-9	3479-3488	inspected	_
18-10	3489-3491	by	_
18-11	3492-3494	an	_
18-12	3495-3506	experienced	_
18-13	3507-3523	neuroradiologist	_
18-14	3524-3526	to	_
18-15	3527-3534	exclude	_
18-16	3535-3546	significant	_
18-17	3547-3557	structural	_
18-18	3558-3571	abnormalities	_
18-19	3572-3573	,	_
18-20	3574-3577	e.g	_
18-21	3578-3579	.	_

19-1	3580-3586	tumors	_
19-2	3587-3588	,	_
19-3	3589-3591	in	_
19-4	3592-3595	all	_
19-5	3596-3608	participants	_
19-6	3609-3610	.	_

20-1	3611-3614	The	_
20-2	3615-3620	study	_
20-3	3621-3624	was	_
20-4	3625-3633	approved	_
20-5	3634-3636	by	_
20-6	3637-3640	the	_
20-7	3641-3654	institutional	_
20-8	3655-3661	review	_
20-9	3662-3667	board	_
20-10	3668-3670	of	_
20-11	3671-3674	the	_
20-12	3675-3685	University	_
20-13	3686-3688	of	_
20-14	3689-3697	Illinois	_
20-15	3698-3700	at	_
20-16	3701-3708	Chicago	_
20-17	3709-3712	and	_
20-18	3713-3720	written	_
20-19	3721-3729	informed	_
20-20	3730-3737	consent	_
20-21	3738-3741	was	_
20-22	3742-3750	obtained	_
20-23	3751-3756	prior	_
20-24	3757-3759	to	_
20-25	3760-3765	study	_
20-26	3766-3779	participation	_
20-27	3780-3781	.	_

21-1	3782-3785	Eye	_
21-2	3786-3794	movement	_
21-3	3795-3802	testing	_
21-4	3803-3814	Antisaccade	_
21-5	3815-3822	testing	_
21-6	3823-3826	and	_
21-7	3827-3835	analysis	_
21-8	3836-3846	procedures	_
21-9	3847-3851	have	_
21-10	3852-3856	been	_
21-11	3857-3866	described	_
21-12	3867-3869	in	_
21-13	3870-3876	detail	_
21-14	3877-3887	previously	_
21-15	3888-3889	.	_

22-1	3890-3893	Eye	_
22-2	3894-3903	movements	_
22-3	3904-3908	were	_
22-4	3909-3917	acquired	_
22-5	3918-3922	with	_
22-6	3923-3924	a	_
22-7	3925-3936	video-based	_
22-8	3937-3940	eye	_
22-9	3941-3948	tracker	_
22-10	3949-3951	in	_
22-11	3952-3953	a	_
22-12	3954-3962	darkened	_
22-13	3963-3967	room	_
22-14	3968-3969	(	_
22-15	3970-3977	Eyelink	_
22-16	3978-3980	II	_
22-17	3981-3982	,	_
22-18	3983-3985	SR	_
22-19	3986-3994	Research	_
22-20	3995-3999	Ltd.	_
22-21	4000-4001	,	_
22-22	4002-4016	Ontario/Canada	_
22-23	4017-4018	,	_
22-24	4019-4027	sampling	_
22-25	4028-4032	rate	_
22-26	4033-4036	500	_
22-27	4037-4039	Hz	_
22-28	4040-4041	)	_
22-29	4042-4043	.	_

23-1	4044-4050	Before	_
23-2	4051-4058	testing	_
23-3	4059-4060	,	_
23-4	4061-4073	participants	_
23-5	4074-4083	refrained	_
23-6	4084-4088	from	_
23-7	4089-4097	nicotine	_
23-8	4098-4100	or	_
23-9	4101-4109	caffeine	_
23-10	4110-4118	exposure	_
23-11	4119-4122	for	_
23-12	4123-4125	at	_
23-13	4126-4131	least	_
23-14	4132-4134	30	_
23-15	4135-4142	minutes	_
23-16	4143-4144	.	_

24-1	4145-4149	They	_
24-2	4150-4154	were	_
24-3	4155-4161	seated	_
24-4	4162-4164	60	_
24-5	4165-4167	cm	_
24-6	4168-4172	from	_
24-7	4173-4174	a	_
24-8	4175-4182	22-inch	_
24-9	4183-4186	CRT	_
24-10	4187-4194	monitor	_
24-11	4195-4196	(	_
24-12	4197-4201	1360	_
24-13	4202-4203	×	_
24-14	4204-4207	768	_
24-15	4208-4218	resolution	_
24-16	4219-4220	;	_
24-17	4221-4224	150	_
24-18	4225-4227	Hz	_
24-19	4228-4235	refresh	_
24-20	4236-4240	rate	_
24-21	4241-4242	)	_
24-22	4243-4247	with	_
24-23	4248-4253	their	_
24-24	4254-4259	heads	_
24-25	4260-4270	stabilized	_
24-26	4271-4275	with	_
24-27	4276-4277	a	_
24-28	4278-4282	chin	_
24-29	4283-4286	and	_
24-30	4287-4295	forehead	_
24-31	4296-4305	restraint	_
24-32	4306-4307	.	_

25-1	4308-4311	The	_
25-2	4312-4318	target	_
25-3	4319-4322	was	_
25-4	4323-4324	a	_
25-5	4325-4328	red	_
25-6	4329-4334	cross	_
25-7	4335-4337	in	_
25-8	4338-4339	a	_
25-9	4340-4343	box	_
25-10	4344-4352	covering	_
25-11	4353-4357	0.5°	_
25-12	4358-4359	.	_

26-1	4360-4363	The	http://maven.renci.org/NeuroBridge/neurobridge#DementiaoftheLewyBodyType
26-2	4364-4375	antisaccade	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-3	4376-4380	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-4	4381-4390	consisted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-5	4391-4393	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-6	4394-4396	80	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-7	4397-4404	overlap	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-8	4405-4411	trials	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-9	4412-4419	divided	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-10	4420-4424	into	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-11	4425-4429	four	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-12	4430-4436	blocks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
26-13	4437-4438	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging

27-1	4439-4444	After	_
27-2	4445-4446	a	_
27-3	4447-4453	period	_
27-4	4454-4456	of	_
27-5	4457-4464	central	_
27-6	4465-4473	fixation	_
27-7	4474-4475	(	_
27-8	4476-4480	1500	_
27-9	4481-4482	–	_
27-10	4483-4487	2500	_
27-11	4488-4492	msec	_
27-12	4493-4494	)	_
27-13	4495-4496	,	_
27-14	4497-4500	the	_
27-15	4501-4508	central	_
27-16	4509-4515	target	_
27-17	4516-4519	was	_
27-18	4520-4532	extinguished	_
27-19	4533-4538	200ms	_
27-20	4539-4544	after	_
27-21	4545-4555	peripheral	_
27-22	4556-4562	target	_
27-23	4563-4573	appearance	_
27-24	4574-4576	at	_
27-25	4577-4583	either	_
27-26	4584-4587	10°	_
27-27	4588-4590	or	_
27-28	4591-4594	15°	_
27-29	4595-4597	to	_
27-30	4598-4601	the	_
27-31	4602-4606	left	_
27-32	4607-4609	or	_
27-33	4610-4615	right	_
27-34	4616-4620	from	_
27-35	4621-4627	center	_
27-36	4628-4629	.	_

28-1	4630-4638	Subjects	_
28-2	4639-4643	were	_
28-3	4644-4654	instructed	_
28-4	4655-4657	to	_
28-5	4658-4661	not	_
28-6	4662-4666	look	_
28-7	4667-4669	to	_
28-8	4670-4673	the	_
28-9	4674-4684	peripheral	_
28-10	4685-4691	target	_
28-11	4692-4693	(	_
28-12	4694-4705	antisaccade	_
28-13	4706-4711	error	_
28-14	4712-4713	)	_
28-15	4714-4717	but	_
28-16	4718-4725	instead	_
28-17	4726-4737	immediately	_
28-18	4738-4742	look	_
28-19	4743-4745	to	_
28-20	4746-4749	the	_
28-21	4750-4756	mirror	_
28-22	4757-4762	image	_
28-23	4763-4771	location	_
28-24	4772-4774	in	_
28-25	4775-4778	the	_
28-26	4779-4787	opposite	_
28-27	4788-4798	hemi-field	_
28-28	4799-4800	.	_

29-1	4801-4804	The	_
29-2	4805-4815	percentage	_
29-3	4816-4818	of	_
29-4	4819-4825	trials	_
29-5	4826-4830	with	_
29-6	4831-4842	antisaccade	_
29-7	4843-4849	errors	_
29-8	4850-4853	was	_
29-9	4854-4862	recorded	_
29-10	4863-4873	indicating	_
29-11	4874-4880	failed	_
29-12	4881-4891	inhibitory	_
29-13	4892-4899	control	_
29-14	4900-4901	.	_

30-1	4902-4905	The	_
30-2	4906-4910	mean	_
30-3	4911-4918	latency	_
30-4	4919-4921	of	_
30-5	4922-4929	correct	_
30-6	4930-4942	antisaccades	_
30-7	4943-4946	for	_
30-8	4947-4951	each	_
30-9	4952-4959	subject	_
30-10	4960-4963	was	_
30-11	4964-4968	also	_
30-12	4969-4979	determined	_
30-13	4980-4981	,	_
30-14	4982-4987	which	_
30-15	4988-4996	reflects	_
30-16	4997-5001	time	_
30-17	5002-5004	to	_
30-18	5005-5012	inhibit	_
30-19	5013-5015	an	_
30-20	5016-5027	antisaccade	_
30-21	5028-5033	error	_
30-22	5034-5037	and	_
30-23	5038-5047	implement	_
30-24	5048-5050	of	_
30-25	5051-5067	task-appropriate	_
30-26	5068-5075	correct	_
30-27	5076-5089	goal-directed	_
30-28	5090-5099	voluntary	_
30-29	5100-5108	behavior	_
30-30	5109-5110	.	_

31-1	5111-5118	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-2	5119-5124	State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-3	5125-5129	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-4	5130-5134	Data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-5	5135-5146	Acquisition	_
31-6	5147-5152	Brain	_
31-7	5153-5158	scans	_
31-8	5159-5163	were	_
31-9	5164-5173	conducted	_
31-10	5174-5179	using	_
31-11	5180-5181	a	_
31-12	5182-5184	GE	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-13	5185-5190	Signa	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-14	5191-5197	EXCITE	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-15	5198-5201	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-16	5202-5207	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-17	5208-5210	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-18	5211-5218	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-19	5219-5225	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-20	5226-5229	and	_
31-21	5230-5232	an	_
31-22	5233-5242	8-channel	_
31-23	5243-5249	phased	_
31-24	5250-5255	array	_
31-25	5256-5260	head	_
31-26	5261-5265	coil	_
31-27	5266-5267	.	_

32-1	5268-5281	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-2	5282-5284	MR	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-3	5285-5293	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-4	5294-5297	was	_
32-5	5298-5307	performed	_
32-6	5308-5313	while	_
32-7	5314-5322	subjects	_
32-8	5323-5330	fixated	_
32-9	5331-5332	a	_
32-10	5333-5340	central	_
32-11	5341-5350	crosshair	_
32-12	5351-5354	for	_
32-13	5355-5358	the	_
32-14	5359-5367	duration	_
32-15	5368-5370	of	_
32-16	5371-5372	a	_
32-17	5373-5381	5-minute	_
32-18	5382-5386	scan	_
32-19	5387-5388	.	_

33-1	5389-5394	Video	_
33-2	5395-5405	monitoring	_
33-3	5406-5408	of	_
33-4	5409-5421	participants	_
33-5	5422-5423	’	_
33-6	5424-5428	eyes	_
33-7	5429-5438	confirmed	_
33-8	5439-5448	adherence	_
33-9	5449-5451	to	_
33-10	5452-5456	this	_
33-11	5457-5468	instruction	_
33-12	5469-5470	.	_

34-1	5471-5475	Soft	_
34-2	5476-5479	ear	_
34-3	5480-5485	plugs	_
34-4	5486-5490	were	_
34-5	5491-5495	used	_
34-6	5496-5498	to	_
34-7	5499-5505	reduce	_
34-8	5506-5510	scan	_
34-9	5511-5516	noise	_
34-10	5517-5518	,	_
34-11	5519-5522	and	_
34-12	5523-5527	head	_
34-13	5528-5534	motion	_
34-14	5535-5538	was	_
34-15	5539-5548	minimized	_
34-16	5549-5553	with	_
34-17	5554-5558	head	_
34-18	5559-5567	cushions	_
34-19	5568-5569	.	_

35-1	5570-5576	During	_
35-2	5577-5585	scanning	_
35-3	5586-5587	,	_
35-4	5588-5596	subjects	_
35-5	5597-5601	were	_
35-6	5602-5612	instructed	_
35-7	5613-5615	to	_
35-8	5616-5621	relax	_
35-9	5622-5626	with	_
35-10	5627-5631	eyes	_
35-11	5632-5638	closed	_
35-12	5639-5640	,	_
35-13	5641-5648	without	_
35-14	5649-5656	falling	_
35-15	5657-5663	asleep	_
35-16	5664-5667	and	_
35-17	5668-5675	without	_
35-18	5676-5684	directed	_
35-19	5685-5686	,	_
35-20	5687-5697	systematic	_
35-21	5698-5705	thought	_
35-22	5706-5707	.	_

36-1	5708-5719	Echo-planar	_
36-2	5720-5727	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
36-3	5728-5729	(	_
36-4	5730-5740	repetition	_
36-5	5741-5746	time=	_
36-6	5747-5755	1775msec	_
36-7	5756-5757	,	_
36-8	5758-5762	echo	_
36-9	5763-5768	time=	_
36-10	5769-5775	27msec	_
36-11	5776-5777	,	_
36-12	5778-5782	flip	_
36-13	5783-5789	angle=	_
36-14	5790-5793	60°	_
36-15	5794-5795	)	_
36-16	5796-5799	was	_
36-17	5800-5809	performed	_
36-18	5810-5814	with	_
36-19	5815-5820	slice	_
36-20	5821-5830	thickness	_
36-21	5831-5833	of	_
36-22	5834-5835	4	_
36-23	5836-5838	mm	_
36-24	5839-5840	(	_
36-25	5841-5844	1mm	_
36-26	5845-5848	gap	_
36-27	5849-5850	)	_
36-28	5851-5852	,	_
36-29	5853-5854	a	_
36-30	5855-5861	matrix	_
36-31	5862-5866	size	_
36-32	5867-5869	of	_
36-33	5870-5875	64×64	_
36-34	5876-5879	and	_
36-35	5880-5881	a	_
36-36	5882-5887	field	_
36-37	5888-5890	of	_
36-38	5891-5895	view	_
36-39	5896-5898	of	_
36-40	5899-5906	220×220	_
36-41	5907-5910	mm²	_
36-42	5911-5912	,	_
36-43	5913-5922	resulting	_
36-44	5923-5925	in	_
36-45	5926-5927	a	_
36-46	5928-5933	voxel	_
36-47	5934-5938	size	_
36-48	5939-5942	for	_
36-49	5943-5951	analysis	_
36-50	5952-5954	of	_
36-51	5955-5966	3.44×3.44×5	_
36-52	5967-5969	mm	_
36-53	5970-5971	.	_

37-1	5972-5976	Each	_
37-2	5977-5982	brain	_
37-3	5983-5989	volume	_
37-4	5990-5993	was	_
37-5	5994-6003	comprised	_
37-6	6004-6006	of	_
37-7	6007-6009	29	_
37-8	6010-6015	axial	_
37-9	6016-6022	slices	_
37-10	6023-6024	,	_
37-11	6025-6028	and	_
37-12	6029-6033	each	_
37-13	6034-6044	functional	_
37-14	6045-6048	run	_
37-15	6049-6058	contained	_
37-16	6059-6062	210	_
37-17	6063-6068	image	_
37-18	6069-6076	volumes	_
37-19	6077-6078	.	_

38-1	6079-6086	Resting	_
38-2	6087-6092	State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-3	6093-6097	Data	_
38-4	6098-6106	Analyses	_
38-5	6107-6116	Amplitude	_
38-6	6117-6119	of	_
38-7	6120-6123	low	_
38-8	6124-6133	frequency	_
38-9	6134-6146	fluctuations	_
38-10	6147-6148	(	_
38-11	6149-6153	ALFF	_
38-12	6154-6155	)	_
38-13	6156-6170	Pre-processing	_
38-14	6171-6176	steps	_
38-15	6177-6181	were	_
38-16	6182-6191	performed	_
38-17	6192-6197	using	_
38-18	6198-6201	the	_
38-19	6202-6206	Data	_
38-20	6207-6217	Processing	_
38-21	6218-6227	Assistant	_
38-22	6228-6231	for	_
38-23	6232-6245	Resting-State	_
38-24	6246-6250	fMRI	_
38-25	6251-6252	(	_
38-26	6253-6259	DPARSF	_
38-27	6260-6261	)	_
38-28	6262-6269	toolbox	_
38-29	6270-6274	that	_
38-30	6275-6279	runs	_
38-31	6280-6282	on	_
38-32	6283-6286	the	_
38-33	6287-6291	REST	_
38-34	6292-6300	software	_
38-35	6301-6309	platform	_
38-36	6310-6311	(	_
38-37	6312-6316	http	_
38-38	6317-6318	:	_
38-39	6319-6349	//resting-fmri.sourceforge.net	_
38-40	6350-6351	)	_
38-41	6352-6353	.	_

39-1	6354-6357	The	_
39-2	6358-6363	first	_
39-3	6364-6368	five	_
39-4	6369-6374	scans	_
39-5	6375-6379	were	_
39-6	6380-6389	discarded	_
39-7	6390-6392	to	_
39-8	6393-6402	establish	_
39-9	6403-6416	magnetization	_
39-10	6417-6430	stabilization	_
39-11	6431-6432	.	_

40-1	6433-6436	For	_
40-2	6437-6441	each	_
40-3	6442-6449	subject	_
40-4	6450-6451	,	_
40-5	6452-6455	EPI	_
40-6	6456-6462	images	_
40-7	6463-6467	were	_
40-8	6468-6480	slice-timing	_
40-9	6481-6490	corrected	_
40-10	6491-6492	,	_
40-11	6493-6496	and	_
40-12	6497-6506	realigned	_
40-13	6507-6509	to	_
40-14	6510-6513	the	_
40-15	6514-6520	middle	_
40-16	6521-6526	slice	_
40-17	6527-6528	.	_

41-1	6529-6532	The	_
41-2	6533-6540	Friston	_
41-3	6541-6553	24-parameter	_
41-4	6554-6559	model	_
41-5	6560-6563	was	_
41-6	6564-6568	used	_
41-7	6569-6571	to	_
41-8	6572-6579	regress	_
41-9	6580-6583	out	_
41-10	6584-6588	head	_
41-11	6589-6595	motion	_
41-12	6596-6603	effects	_
41-13	6604-6608	from	_
41-14	6609-6612	the	_
41-15	6613-6622	realigned	_
41-16	6623-6627	data	_
41-17	6628-6629	,	_
41-18	6630-6635	which	_
41-19	6636-6639	has	_
41-20	6640-6652	demonstrated	_
41-21	6653-6661	benefits	_
41-22	6662-6664	in	_
41-23	6665-6673	removing	_
41-24	6674-6678	head	_
41-25	6679-6685	motion	_
41-26	6686-6693	effects	_
41-27	6694-6696	in	_
41-28	6697-6703	recent	_
41-29	6704-6711	reports	_
41-30	6712-6713	.	_

42-1	6714-6720	Motion	_
42-2	6721-6730	scrubbing	_
42-3	6731-6734	was	_
42-4	6735-6738	not	_
42-5	6739-6746	applied	_
42-6	6747-6749	to	_
42-7	6750-6755	avoid	_
42-8	6756-6759	the	_
42-9	6760-6771	possibility	_
42-10	6772-6774	of	_
42-11	6775-6781	losing	_
42-12	6782-6786	data	_
42-13	6787-6794	leading	_
42-14	6795-6797	to	_
42-15	6798-6799	a	_
42-16	6800-6806	biased	_
42-17	6807-6815	estimate	_
42-18	6816-6818	of	_
42-19	6819-6826	further	_
42-20	6827-6834	distant	_
42-21	6835-6847	connectivity	_
42-22	6848-6849	,	_
42-23	6850-6862	specifically	_
42-24	6863-6865	in	_
42-25	6866-6872	visual	_
42-26	6873-6876	and	_
42-27	6877-6886	posterior	_
42-28	6887-6895	parietal	_
42-29	6896-6903	regions	_
42-30	6904-6905	.	_

43-1	6906-6910	Next	_
43-2	6911-6912	,	_
43-3	6913-6923	functional	_
43-4	6924-6930	images	_
43-5	6931-6935	were	_
43-6	6936-6945	spatially	_
43-7	6946-6956	normalized	_
43-8	6957-6959	to	_
43-9	6960-6963	the	_
43-10	6964-6972	Montreal	_
43-11	6973-6985	Neurological	_
43-12	6986-6995	Institute	_
43-13	6996-6997	(	_
43-14	6998-7001	MNI	_
43-15	7002-7003	)	_
43-16	7004-7007	EPI	_
43-17	7008-7016	template	_
43-18	7017-7019	in	_
43-19	7020-7024	SPM8	_
43-20	7025-7026	,	_
43-21	7027-7036	resampled	_
43-22	7037-7039	to	_
43-23	7040-7048	3×3×3mm³	_
43-24	7049-7050	,	_
43-25	7051-7054	and	_
43-26	7055-7063	smoothed	_
43-27	7064-7068	with	_
43-28	7069-7071	an	_
43-29	7072-7076	6-mm	_
43-30	7077-7087	full-width	_
43-31	7088-7090	at	_
43-32	7091-7103	half-maximum	_
43-33	7104-7105	(	_
43-34	7106-7110	FWHM	_
43-35	7111-7112	)	_
43-36	7113-7121	Gaussian	_
43-37	7122-7128	kernel	_
43-38	7129-7130	.	_

44-1	7131-7142	Measurement	_
44-2	7143-7145	of	_
44-3	7146-7149	the	_
44-4	7150-7159	amplitude	_
44-5	7160-7162	of	_
44-6	7163-7176	low-frequency	_
44-7	7177-7189	fluctuations	_
44-8	7190-7192	of	_
44-9	7193-7196	the	_
44-10	7197-7201	BOLD	_
44-11	7202-7208	signal	_
44-12	7209-7210	(	_
44-13	7211-7215	ALFF	_
44-14	7216-7217	)	_
44-15	7218-7219	,	_
44-16	7220-7230	considered	_
44-17	7231-7233	to	_
44-18	7234-7236	be	_
44-19	7237-7244	related	_
44-20	7245-7247	to	_
44-21	7248-7256	regional	_
44-22	7257-7268	spontaneous	_
44-23	7269-7275	neural	_
44-24	7276-7284	activity	_
44-25	7285-7286	,	_
44-26	7287-7290	was	_
44-27	7291-7295	used	_
44-28	7296-7298	to	_
44-29	7299-7307	identify	_
44-30	7308-7319	differences	_
44-31	7320-7327	between	_
44-32	7328-7331	the	_
44-33	7332-7339	patient	_
44-34	7340-7345	group	_
44-35	7346-7349	and	_
44-36	7350-7358	controls	_
44-37	7359-7361	in	_
44-38	7362-7370	regional	_
44-39	7371-7378	resting	_
44-40	7379-7387	cerebral	_
44-41	7388-7396	function	_
44-42	7397-7398	.	_

45-1	7399-7404	After	_
45-2	7405-7413	bandpass	_
45-3	7414-7423	filtering	_
45-4	7424-7425	(	_
45-5	7426-7435	0.01–0.08	_
45-6	7436-7438	Hz	_
45-7	7439-7440	)	_
45-8	7441-7442	,	_
45-9	7443-7450	signals	_
45-10	7451-7455	from	_
45-11	7456-7461	white	_
45-12	7462-7468	matter	_
45-13	7469-7472	and	_
45-14	7473-7486	cerebrospinal	_
45-15	7487-7492	fluid	_
45-16	7493-7497	were	_
45-17	7498-7505	removed	_
45-18	7506-7507	.	_

46-1	7508-7517	Following	_
46-2	7518-7524	linear	_
46-3	7525-7535	detrending	_
46-4	7536-7537	,	_
46-5	7538-7541	the	_
46-6	7542-7552	voxel-wise	_
46-7	7553-7557	time	_
46-8	7558-7564	series	_
46-9	7565-7569	were	_
46-10	7570-7581	transformed	_
46-11	7582-7584	to	_
46-12	7585-7588	the	_
46-13	7589-7598	frequency	_
46-14	7599-7605	domain	_
46-15	7606-7611	using	_
46-16	7612-7616	fast	_
46-17	7617-7624	Fourier	_
46-18	7625-7639	transformation	_
46-19	7640-7642	to	_
46-20	7643-7649	obtain	_
46-21	7650-7653	the	_
46-22	7654-7659	power	_
46-23	7660-7668	spectrum	_
46-24	7669-7670	.	_

47-1	7671-7674	The	_
47-2	7675-7679	ALFF	_
47-3	7680-7687	measure	_
47-4	7688-7690	at	_
47-5	7691-7695	each	_
47-6	7696-7701	voxel	_
47-7	7702-7712	represents	_
47-8	7713-7716	the	_
47-9	7717-7723	square	_
47-10	7724-7728	root	_
47-11	7729-7731	of	_
47-12	7732-7735	the	_
47-13	7736-7741	power	_
47-14	7742-7748	across	_
47-15	7749-7750	a	_
47-16	7751-7764	low-frequency	_
47-17	7765-7770	range	_
47-18	7771-7772	.	_

48-1	7773-7776	The	_
48-2	7777-7781	ALFF	_
48-3	7782-7787	value	_
48-4	7788-7790	of	_
48-5	7791-7795	each	_
48-6	7796-7801	voxel	_
48-7	7802-7805	was	_
48-8	7806-7813	divided	_
48-9	7814-7816	by	_
48-10	7817-7820	the	_
48-11	7821-7827	global	_
48-12	7828-7832	mean	_
48-13	7833-7837	ALFF	_
48-14	7838-7843	value	_
48-15	7844-7846	of	_
48-16	7847-7851	each	_
48-17	7852-7862	individual	_
48-18	7863-7870	subject	_
48-19	7871-7873	to	_
48-20	7874-7885	standardize	_
48-21	7886-7890	data	_
48-22	7891-7894	for	_
48-23	7895-7906	comparisons	_
48-24	7907-7913	across	_
48-25	7914-7922	subjects	_
48-26	7923-7924	.	_

49-1	7925-7935	Functional	_
49-2	7936-7948	connectivity	_
49-3	7949-7957	analysis	_
49-4	7958-7960	To	_
49-5	7961-7972	investigate	_
49-6	7973-7983	functional	_
49-7	7984-7993	circuitry	_
49-8	7994-8005	alterations	_
49-9	8006-8007	,	_
49-10	8008-8010	we	_
49-11	8011-8016	first	_
49-12	8017-8027	identified	_
49-13	8028-8036	regional	_
49-14	8037-8042	group	_
49-15	8043-8054	differences	_
49-16	8055-8057	of	_
49-17	8058-8062	ALFF	_
49-18	8063-8069	values	_
49-19	8070-8071	.	_

50-1	8072-8077	These	_
50-2	8078-8082	were	_
50-3	8083-8087	used	_
50-4	8088-8090	to	_
50-5	8091-8097	create	_
50-6	8098-8102	seed	_
50-7	8103-8110	regions	_
50-8	8111-8114	for	_
50-9	8115-8125	functional	_
50-10	8126-8138	connectivity	_
50-11	8139-8147	analyses	_
50-12	8148-8150	by	_
50-13	8151-8159	creating	_
50-14	8160-8161	a	_
50-15	8162-8171	spherical	_
50-16	8172-8178	region	_
50-17	8179-8181	of	_
50-18	8182-8190	interest	_
50-19	8191-8199	centered	_
50-20	8200-8202	on	_
50-21	8203-8206	the	_
50-22	8207-8212	voxel	_
50-23	8213-8217	with	_
50-24	8218-8222	peak	_
50-25	8223-8228	group	_
50-26	8229-8239	difference	_
50-27	8240-8242	in	_
50-28	8243-8247	ALFF	_
50-29	8248-8252	data	_
50-30	8253-8257	that	_
50-31	8258-8261	had	_
50-32	8262-8263	a	_
50-33	8264-8270	radius	_
50-34	8271-8273	of	_
50-35	8274-8277	3mm	_
50-36	8278-8279	.	_

51-1	8280-8286	Voxels	_
51-2	8287-8289	in	_
51-3	8290-8293	the	_
51-4	8294-8300	region	_
51-5	8301-8303	of	_
51-6	8304-8312	interest	_
51-7	8313-8319	sphere	_
51-8	8320-8324	were	_
51-9	8325-8333	averaged	_
51-10	8334-8336	to	_
51-11	8337-8343	create	_
51-12	8344-8347	the	_
51-13	8348-8352	seed	_
51-14	8353-8356	for	_
51-15	8357-8359	FC	_
51-16	8360-8368	analysis	_
51-17	8369-8376	between	_
51-18	8377-8380	eye	_
51-19	8381-8389	movement	_
51-20	8390-8398	relevant	_
51-21	8399-8406	regions	_
51-22	8407-8411	with	_
51-23	8412-8419	altered	_
51-24	8420-8424	ALFF	_
51-25	8425-8431	values	_
51-26	8432-8435	and	_
51-27	8436-8439	the	_
51-28	8440-8449	remainder	_
51-29	8450-8452	of	_
51-30	8453-8456	the	_
51-31	8457-8462	brain	_
51-32	8463-8464	.	_

52-1	8465-8468	The	_
52-2	8469-8474	first	_
52-3	8475-8479	step	_
52-4	8480-8482	in	_
52-5	8483-8486	the	_
52-6	8487-8495	analysis	_
52-7	8496-8499	was	_
52-8	8500-8502	to	_
52-9	8503-8510	extract	_
52-10	8511-8512	a	_
52-11	8513-8522	reference	_
52-12	8523-8527	time	_
52-13	8528-8534	series	_
52-14	8535-8537	by	_
52-15	8538-8547	obtaining	_
52-16	8548-8551	the	_
52-17	8552-8559	average	_
52-18	8560-8562	of	_
52-19	8563-8566	the	_
52-20	8567-8571	time	_
52-21	8572-8578	series	_
52-22	8579-8581	of	_
52-23	8582-8588	voxels	_
52-24	8589-8595	within	_
52-25	8596-8600	each	_
52-26	8601-8607	sphere	_
52-27	8608-8610	as	_
52-28	8611-8620	described	_
52-29	8621-8626	above	_
52-30	8627-8628	.	_

53-1	8629-8641	Correlations	_
53-2	8642-8646	were	_
53-3	8647-8651	then	_
53-4	8652-8660	computed	_
53-5	8661-8668	between	_
53-6	8669-8672	the	_
53-7	8673-8677	time	_
53-8	8678-8684	series	_
53-9	8685-8687	of	_
53-10	8688-8691	the	_
53-11	8692-8696	seed	_
53-12	8697-8706	reference	_
53-13	8707-8710	and	_
53-14	8711-8714	all	_
53-15	8715-8720	brain	_
53-16	8721-8727	voxels	_
53-17	8728-8735	outside	_
53-18	8736-8739	the	_
53-19	8740-8744	seed	_
53-20	8745-8751	region	_
53-21	8752-8753	.	_

54-1	8754-8761	Finally	_
54-2	8762-8763	,	_
54-3	8764-8769	these	_
54-4	8770-8781	correlation	_
54-5	8782-8794	coefficients	_
54-6	8795-8799	were	_
54-7	8800-8811	transformed	_
54-8	8812-8814	by	_
54-9	8815-8821	Fisher	_
54-10	8822-8828	r-to-z	_
54-11	8829-8843	transformation	_
54-12	8844-8846	to	_
54-13	8847-8855	increase	_
54-14	8856-8861	their	_
54-15	8862-8871	normality	_
54-16	8872-8878	before	_
54-17	8879-8888	averaging	_
54-18	8889-8901	correlations	_
54-19	8902-8908	across	_
54-20	8909-8921	participants	_
54-21	8922-8925	and	_
54-22	8926-8933	testing	_
54-23	8934-8937	for	_
54-24	8938-8950	associations	_
54-25	8951-8955	with	_
54-26	8956-8967	antisaccade	_
54-27	8968-8972	task	_
54-28	8973-8984	performance	_
54-29	8985-8986	.	_

55-1	8987-8998	Statistical	_
55-2	8999-9007	analyses	_
55-3	9008-9019	Voxel-based	_
55-4	9020-9030	comparison	_
55-5	9031-9033	of	_
55-6	9034-9038	ALFF	_
55-7	9039-9043	maps	_
55-8	9044-9048	from	_
55-9	9049-9056	patient	_
55-10	9057-9060	and	_
55-11	9061-9068	control	_
55-12	9069-9075	groups	_
55-13	9076-9079	was	_
55-14	9080-9089	performed	_
55-15	9090-9095	using	_
55-16	9096-9104	pairwise	_
55-17	9105-9106	t	_
55-18	9107-9112	tests	_
55-19	9113-9115	in	_
55-20	9116-9120	SPM8	_
55-21	9121-9122	(	_
55-22	9123-9127	http	_
55-23	9128-9129	:	_
55-24	9130-9157	//www.fil.ion.ecl.ac.uk/spm	_
55-25	9158-9159	)	_
55-26	9160-9161	.	_

56-1	9162-9165	Age	_
56-2	9166-9167	,	_
56-3	9168-9171	sex	_
56-4	9172-9175	and	_
56-5	9176-9180	race	_
56-6	9181-9185	were	_
56-7	9186-9190	used	_
56-8	9191-9193	as	_
56-9	9194-9204	covariates	_
56-10	9205-9207	in	_
56-11	9208-9213	group	_
56-12	9214-9225	comparisons	_
56-13	9226-9227	.	_

57-1	9228-9240	Connectivity	_
57-2	9241-9244	was	_
57-3	9245-9253	examined	_
57-4	9254-9258	from	_
57-5	9259-9262	the	_
57-6	9263-9271	selected	_
57-7	9272-9276	seed	_
57-8	9277-9282	areas	_
57-9	9283-9288	using	_
57-10	9289-9297	pairwise	_
57-11	9298-9305	t-tests	_
57-12	9306-9315	comparing	_
57-13	9316-9324	patients	_
57-14	9325-9328	and	_
57-15	9329-9337	controls	_
57-16	9338-9339	.	_

58-1	9340-9342	In	_
58-2	9343-9346	all	_
58-3	9347-9352	image	_
58-4	9353-9361	analyses	_
58-5	9362-9363	,	_
58-6	9364-9365	a	_
58-7	9366-9375	threshold	_
58-8	9376-9378	of	_
58-9	9379-9385	p=0.05	_
58-10	9386-9391	after	_
58-11	9392-9400	AlphaSim	_
58-12	9401-9411	correction	_
58-13	9412-9415	was	_
58-14	9416-9420	used	_
58-15	9421-9423	to	_
58-16	9424-9431	correct	_
58-17	9432-9435	for	_
58-18	9436-9444	multiple	_
58-19	9445-9456	comparisons	_
58-20	9457-9470	corresponding	_
58-21	9471-9473	to	_
58-22	9474-9475	a	_
58-23	9476-9483	minimum	_
58-24	9484-9491	cluster	_
58-25	9492-9496	size	_
58-26	9497-9499	of	_
58-27	9500-9502	80	_
58-28	9503-9513	contiguous	_
58-29	9514-9520	voxels	_
58-30	9521-9532	significant	_
58-31	9533-9545	individually	_
58-32	9546-9548	at	_
58-33	9549-9550	a	_
58-34	9551-9560	threshold	_
58-35	9561-9563	of	_
58-36	9564-9565	p	_
58-37	9566-9567	<	_
58-38	9568-9572	0.01	_
58-39	9573-9574	.	_

59-1	9575-9578	The	_
59-2	9579-9587	AlphaSim	_
59-3	9588-9599	calculation	_
59-4	9600-9605	based	_
59-5	9606-9608	on	_
59-6	9609-9614	Monte	_
59-7	9615-9620	Carlo	_
59-8	9621-9632	simulations	_
59-9	9633-9636	was	_
59-10	9637-9646	conducted	_
59-11	9647-9652	using	_
59-12	9653-9657	REST	_
59-13	9658-9666	software	_
59-14	9667-9668	(	_
59-15	9669-9673	http	_
59-16	9674-9675	:	_
59-17	9676-9706	//restfmri.net/forum/index.php	_
59-18	9707-9708	)	_
59-19	9709-9710	.	_

60-1	9711-9713	To	_
60-2	9714-9723	determine	_
60-3	9724-9733	relations	_
60-4	9734-9741	between	_
60-5	9742-9753	alterations	_
60-6	9754-9756	of	_
60-7	9757-9761	mean	_
60-8	9762-9766	ALFF	_
60-9	9767-9770	and	_
60-10	9771-9773	FC	_
60-11	9774-9780	values	_
60-12	9781-9785	with	_
60-13	9786-9797	antisaccade	_
60-14	9798-9809	performance	_
60-15	9810-9818	measures	_
60-16	9819-9820	,	_
60-17	9821-9823	we	_
60-18	9824-9828	used	_
60-19	9829-9837	stepwise	_
60-20	9838-9846	backward	_
60-21	9847-9857	regression	_
60-22	9858-9866	analysis	_
60-23	9867-9871	that	_
60-24	9872-9878	allows	_
60-25	9879-9882	for	_
60-26	9883-9896	consideration	_
60-27	9897-9899	of	_
60-28	9900-9907	several	_
60-29	9908-9919	independent	_
60-30	9920-9929	variables	_
60-31	9930-9944	simultaneously	_
60-32	9945-9946	.	_

61-1	9947-9951	This	_
61-2	9952-9961	procedure	_
61-3	9962-9969	yielded	_
61-4	9970-9971	a	_
61-5	9972-9982	regression	_
61-6	9983-9988	model	_
61-7	9989-9994	using	_
61-8	9995-10002	imaging	_
61-9	10003-10013	parameters	_
61-10	10014-10016	to	_
61-11	10017-10024	predict	_
61-12	10025-10036	antisaccade	_
61-13	10037-10048	performance	_
61-14	10049-10053	with	_
61-15	10054-10055	a	_
61-16	10056-10068	significance	_
61-17	10069-10078	threshold	_
61-18	10079-10082	for	_
61-19	10083-10088	entry	_
61-20	10089-10091	of	_
61-21	10092-10096	0.05	_
61-22	10097-10100	and	_
61-23	10101-10105	that	_
61-24	10106-10109	for	_
61-25	10110-10117	removal	_
61-26	10118-10120	of	_
61-27	10121-10125	0.10	_
61-28	10126-10127	.	_

62-1	10128-10140	Standardized	_
62-2	10141-10149	z-scores	_
62-3	10150-10153	for	_
62-4	10154-10165	antisaccade	_
62-5	10166-10171	error	_
62-6	10172-10176	rate	_
62-7	10177-10180	and	_
62-8	10181-10188	latency	_
62-9	10189-10190	,	_
62-10	10191-10198	derived	_
62-11	10199-10203	from	_
62-12	10204-10205	a	_
62-13	10206-10215	normative	_
62-14	10216-10226	regression	_
62-15	10227-10235	approach	_
62-16	10236-10245	described	_
62-17	10246-10256	previously	_
62-18	10257-10258	,	_
62-19	10259-10263	were	_
62-20	10264-10271	entered	_
62-21	10272-10274	as	_
62-22	10275-10284	dependent	_
62-23	10285-10294	variables	_
62-24	10295-10300	while	_
62-25	10301-10305	mean	_
62-26	10306-10312	values	_
62-27	10313-10315	of	_
62-28	10316-10320	peak	_
62-29	10321-10339	coordinate-defined	_
62-30	10340-10349	spherical	_
62-31	10350-10357	regions	_
62-32	10358-10360	of	_
62-33	10361-10368	altered	_
62-34	10369-10373	ALFF	_
62-35	10374-10377	and	_
62-36	10378-10385	altered	_
62-37	10386-10388	FC	_
62-38	10389-10397	clusters	_
62-39	10398-10400	in	_
62-40	10401-10409	patients	_
62-41	10410-10414	were	_
62-42	10415-10419	used	_
62-43	10420-10422	as	_
62-44	10423-10434	independent	_
62-45	10435-10444	variables	_
62-46	10445-10447	in	_
62-47	10448-10453	these	_
62-48	10454-10462	analyses	_
62-49	10463-10464	.	_

